Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
STOP-AKI: Ilofotase Alfa in Sepsis-Associated AKI
NCT02182440Phase 2Completed
- Sponsor
- AM-Pharma
- Start
- Dec 2014
- Primary completion
- May 2017
- Modality
- Replacement Enzymes
- Countries
- 11
01
Overview
A Phase 2 trial of ilofotase alfa in sepsis-associated acute kidney injury (S-AKI), sponsored by AM-Pharma. Started Dec 2014; status: completed.
02
Drugs
ilofotase alfa
03
Conditions
sepsis-associated acute kidney injury (S-AKI)
Beyond the preview
Go deeper on NCT02182440.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on NCT02182440.